US 12,358,870 B2
Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
Christopher Lindemann, Fort Collins, CO (US); and Peter J. Stengel, Longmont, CO (US)
Assigned to Peloton Therapeutics, Inc., Dallas, TX (US)
Appl. No. 17/286,581
Filed by Peloton Therapeutics Inc., Kenilworth, NJ (US)
PCT Filed Oct. 23, 2019, PCT No. PCT/US2019/057725
§ 371(c)(1), (2) Date Apr. 19, 2021,
PCT Pub. No. WO2020/092100, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/752,685, filed on Oct. 30, 2018.
Prior Publication US 2021/0387946 A1, Dec. 16, 2021
Int. Cl. C07C 317/22 (2006.01); A61K 9/20 (2006.01); A61K 9/10 (2006.01); A61K 9/14 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 31/277 (2006.01); A61K 47/38 (2006.01); A61P 9/12 (2006.01); A61P 35/00 (2006.01)
CPC C07C 317/22 (2013.01) [A61K 9/2054 (2013.01); A61K 9/2095 (2013.01); C07B 2200/13 (2013.01); C07C 2602/08 (2017.05)] 12 Claims
OG exemplary drawing
 
1. A pharmaceutical solid dosage form for oral delivery of a compound of Formula (I),

OG Complex Work Unit Chemistry
wherein the solid dosage form comprises
a solid dispersion comprising the compound of Formula (I), a pharmaceutically acceptable polymer selected from the group consisting of Hypromellose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), and polyethylene glycol vinyl acetate vinylcaprolactam,
one or more pharmaceutically acceptable excipients comprising a binder, a filler, a disintegrant and a lubricant,
wherein the binder is a microcrystalline cellulose, and
the solid dosage form is a capsule or a tablet.